Beleaguered Mallinckrodt has filed for Chapter 11 bankruptcy protection in the US, overwhelmed with potential claims stemming from its part in the country’s opioid abuse epidemic and a bill for $650m resulting from the way the company calculated rebates for its best-selling drug, the Acthar Gel (repository corticotropin) injectable.
Bankruptcy proceedings initiated in the US Bankruptcy Court for the District of Delaware are intended to provide for a restructuring...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Generics Bulletin for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?